Pfizer, Cystic Fibrosis Foundation in new CF deal

Pfizer Inc. (NYSE:PFE) partnered with the drug development affiliate of the not-for-profit Cystic Fibrosis Foundation to discover and develop therapies to treat cystic fibrosis (CF) in patients with the delta F508 mutation in the CF transmembrane conductance regulator ( CFTR) protein. Under the deal, Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) will invest up to $58 million to develop undisclosed preclinical candidates, with the goal of advancing one or more into the clinic by the end of the six-year program. ...